The U.S. Food and Drug Administration (FDA) announced guidances for medical product developers, specifically covering vaccines, diagnostics, and therapeutics products, to address the emergence and potential future emergence of variants of the SARS-CoV-2 coronavirus.
Ebola vaccination of people at high risk in Guinea launched as an emergency response was escalated, said the World Health Organization (WHO).
The new vaccination program is to counter the spread of the Ebola virus that re-emerged in Guinea’s western Africa country for the first time since 2016.
The vaccination campaign was launched in Gouecke, a rural community in N’Zerekore prefecture, where the first cases were detected on February 14, 2021. N’Zerekore is Guinea’s second-largest city and is close to the border with Liberia and Cote d’Ivoire.
About half of those with compromised sense of smell during acute phase had not regained sense of smell at average of 150.1 days postdiagnosis
Testing people with any of seven key symptoms in the first three days of illness would detect 96 percent of symptomatic cases
By end of March, Pfizer and Moderna expect to have delivered a total of 220 million vaccine doses to the U.S. government
Age, not race, most important contributing factor for outcomes
In mass vaccination setting, vaccine is effective for symptomatic COVID-19, hospitalization, severe disease, death
Advisory panel set to meet Friday to recommend whether the agency should authorize the shot for emergency use
Odds also lower for having severe disease for patients vaccinated for influenza, pneumococcal disease